B-intervention	0	10	Carvedilol
O	11	25	Administration
O	26	29	Can
O	30	37	Prevent
B-condition	38	49	Doxorubicin
I-condition	49	50	-
I-condition	50	57	Induced
I-condition	58	72	Cardiotoxicity
O	72	73	:
O	74	75	A
O	76	82	Double
O	82	83	-
O	83	88	Blind
O	89	99	Randomized
O	100	105	Trial
O	105	106	.

O	107	110	The
O	111	114	aim
O	115	117	of
O	118	122	this
O	123	128	study
O	129	131	is
O	132	134	to
O	135	143	evaluate
O	144	147	the
O	148	158	preventive
O	159	166	effects
O	167	169	of
O	170	180	carvedilol
O	181	183	on
O	184	195	doxorubicin
O	195	196	-
O	196	203	induced
O	204	218	cardiotoxicity
O	218	219	.

O	220	222	In
O	223	227	this
O	228	233	trial
O	233	234	,
B-total-participants	235	237	70
B-eligibility	238	244	female
I-eligibility	245	253	patients
I-eligibility	254	258	with
I-eligibility	259	265	breast
I-eligibility	266	272	cancer
I-eligibility	273	276	who
I-eligibility	277	281	were
I-eligibility	282	292	candidates
I-eligibility	293	295	to
I-eligibility	296	303	receive
I-eligibility	304	315	doxorubicin
O	316	320	were
O	321	329	enrolled
O	329	330	,
O	331	335	from
O	336	341	which
B-intervention-participants	342	344	30
O	345	349	were
O	350	358	selected
O	359	367	randomly
O	368	370	to
O	371	378	receive
O	379	389	carvedilol
O	390	391	6
O	391	392	.
O	392	394	25
O	395	397	mg
O	398	403	daily
O	404	410	during
O	411	423	chemotherapy
O	423	424	,
O	425	429	with
O	430	433	the
O	434	438	rest
O	439	448	receiving
B-control	449	456	placebo
O	457	459	as
O	460	463	the
O	464	471	control
O	472	477	group
O	477	478	.

O	479	483	Both
O	484	490	groups
O	491	495	were
O	496	505	evaluated
O	506	507	1
O	508	512	week
O	513	519	before
O	520	523	and
O	524	525	1
O	526	530	week
O	531	536	after
O	537	549	chemotherapy
O	550	552	by
O	553	562	measuring
O	563	566	the
O	567	571	left
O	572	583	ventricular
O	584	592	ejection
O	593	601	fraction
O	602	605	and
O	606	612	strain
O	612	613	/
O	613	619	strain
O	620	624	rate
O	624	625	.

O	626	630	Data
O	631	639	analysis
O	640	646	showed
O	647	651	that
O	652	655	the
O	656	660	case
O	661	666	group
O	667	676	presented
O	677	679	no
O	680	691	significant
O	692	701	reduction
O	702	704	in
B-outcome	705	711	strain
I-outcome	712	715	and
I-outcome	716	722	strain
I-outcome	722	723	-
I-outcome	723	727	rate
I-outcome	728	738	parameters
O	739	744	after
O	745	757	intervention
O	757	758	,
O	759	764	while
O	765	770	there
O	771	774	was
O	775	776	a
O	777	788	significant
O	789	798	reduction
O	799	801	in
O	802	807	these
O	808	818	parameters
O	819	821	in
O	822	825	the
O	826	833	control
O	834	839	group
O	840	841	(
O	841	844	all
O	845	846	p
O	847	853	values
O	854	855	<
O	855	856	0
O	856	857	.
O	857	860	001
O	860	861	)
O	861	862	.

O	863	867	Also
O	867	868	,
O	869	872	the
B-outcome	873	877	mean
I-outcome	878	889	differences
I-outcome	890	892	of
I-outcome	893	899	strain
I-outcome	900	910	parameters
O	911	913	in
O	914	917	the
O	918	922	case
O	923	928	group
O	929	933	were
O	934	947	significantly
O	948	952	less
O	953	957	than
O	958	960	in
O	961	964	the
O	965	972	control
O	973	978	group
O	979	981	in
O	982	985	all
O	986	995	evaluated
B-outcome	996	1001	heart
I-outcome	1002	1007	walls
O	1008	1009	(
O	1009	1014	basal
O	1015	1021	septal
O	1022	1028	strain
O	1028	1029	,
O	1030	1031	p
O	1032	1033	=
O	1034	1035	0
O	1035	1036	.
O	1036	1039	005
O	1039	1040	,
O	1041	1046	basal
O	1047	1054	lateral
O	1055	1061	strain
O	1061	1062	,
O	1063	1064	p
O	1065	1066	=
O	1067	1068	0
O	1068	1069	.
O	1069	1072	001
O	1072	1073	,
O	1074	1079	basal
O	1080	1088	inferior
O	1089	1095	strain
O	1095	1096	,
O	1097	1098	p
O	1099	1100	<
O	1101	1102	0
O	1102	1103	.
O	1103	1106	001
O	1106	1107	,
O	1108	1111	and
O	1112	1117	basal
O	1118	1126	anterior
O	1127	1133	strain
O	1133	1134	,
O	1135	1136	p
O	1137	1138	<
O	1139	1140	0
O	1140	1141	.
O	1141	1144	001
O	1144	1145	)
O	1145	1146	;
O	1147	1150	the
O	1151	1155	same
O	1156	1159	was
O	1160	1164	true
O	1165	1168	for
O	1169	1172	the
B-outcome	1173	1179	strain
I-outcome	1179	1180	-
I-outcome	1180	1184	rate
I-outcome	1185	1195	parameters
O	1196	1197	(
O	1197	1200	the
O	1201	1202	p
O	1203	1209	values
O	1210	1213	for
O	1214	1219	basal
O	1220	1226	septal
O	1226	1227	,
O	1228	1233	basal
O	1234	1241	lateral
O	1241	1242	,
O	1243	1248	basal
O	1249	1257	inferior
O	1258	1261	and
O	1262	1267	basal
O	1268	1276	anterior
O	1277	1283	strain
O	1284	1288	rate
O	1289	1293	were
O	1294	1295	0
O	1295	1296	.
O	1296	1299	037
O	1299	1300	,
O	1301	1302	0
O	1302	1303	.
O	1303	1306	037
O	1306	1307	,
O	1308	1309	0
O	1309	1310	.
O	1310	1313	002
O	1314	1317	and
O	1318	1319	<
O	1319	1320	0
O	1320	1321	.
O	1321	1324	001
O	1324	1325	,
O	1326	1338	respectively
O	1338	1339	)
O	1339	1340	.

O	1341	1345	This
O	1346	1351	study
O	1352	1357	shows
O	1358	1362	that
O	1363	1373	carvedilol
O	1374	1377	can
O	1378	1385	prevent
O	1386	1397	doxorubicin
O	1397	1398	-
O	1398	1405	induced
O	1406	1420	cardiotoxicity
O	1420	1421	.

O	1422	1429	Whether
O	1430	1434	this
O	1435	1446	prophylaxis
O	1447	1453	should
O	1454	1456	be
O	1457	1467	considered
O	1468	1470	as
O	1471	1474	the
O	1475	1484	preferred
O	1485	1491	method
O	1492	1497	needs
O	1498	1505	further
O	1506	1519	investigation
O	1519	1520	.
